Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1073-1076

  Helbig, Grzegorz ^a   Hus, Marek ^b   Hałasz, Magdalena ^c   Dudziński, Marek ^c   Więcławek, Agnieszka ^a   Stachowicz, Małgorzata ^a   Soja, Anna ^a   Kyrcz Krzemień, Sławomira ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c Provincial Hospital Rzeszow   (Poland)

Author keywords

FIP1L1 PDGFR ; Hypereosinophilic syndrome; Imatinib

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOSPORIN A; HYDROXYUREA; IMATINIB; PREDNISONE; ANTINEOPLASTIC AGENT; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FIP1L1 PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR NEGATIVE HYPEREOSINOPHILIC SYNDROME; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; FOLLOW UP; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863803133     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9831-1     Document Type: Article

References (12)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1-27.
2. Klion A. How I treat hypereosinophilic syndrome. Blood. 2009; 114:3736-41.
3. Cools J, De Angelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Eng J Med. 2003;348:1201-14.
4. Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification and management. Blood. 2004;103:2879-91.
5. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRa-negative hypereosinophilic syndrome. Leuk Res. 2009;33:1127-9.
6. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92:1173-9.
7. Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, et al. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica. 2009;94: 1236-41.
8. Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA- expressing patients. Brit J Haematol. 2008;141:200-4.
9. Metzgeroth G, Walc Z, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukemia and hypereosinophilic syndrome-a phase II study. Brit J Haematol. 2008;143:707-15.
10. Jain N, Cortes J, Quintas-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRa mutation status. Leuk Res. 2009; 33:837-9.
11. Curtis CE, Grand FH, Musto P, et al. Two novel imatinibresponsive PDGFRA fusions genes in chronic eosinophilic leukaemia. Brit J Haematol. 2007;138:77-81.
12. Intermesoli T, Delaini F, Acerboni S, et al. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Brit J Haematol. 2009;147:681-5.